Rameda (RMDA) announced it will start production of the antiviral drug “Molnupiravir Rameda” after it obtained the necessary licenses from the Egyptian Drug Authority (EDA).
More on Molnupiravir💊 Molnupiravir is an antiviral drug approved for the treatment of adult infections with COVID-19. The pill was co-developed by U.S. pharmaceutical giant Merck & Co.
Pfizer had also announced that it is in discussions with 90 countries over supply contracts for its own pill, Paxlovid.
More Details🧐 Rameda is coordinating its production plans with the EDA & the Ministry of Health to ensure that market needs for this drug are met in a timely manner.
The first batch is expected before the end of Q1-2022 at a price of EGP 625/package, with each package containing 40 capsules & a concentration of 200 mg/capsule.
Why is this Important🤔 The addition of Molnupiravir to Rameda’s portfolio will result in an expansion of its share in the fast-growing antiviral market. Rameda’s antiviral drugs contributed 12% to its total revenue during the first nine months of 2021.
RMDA closed 5.53% in the green in yesterday’s trading session.